Context: The Drug Controller General of India (DCGI) has granted market authorization to Takeda Biopharmaceuticals India’s QDENGA (TAK-003), making it the first dengue vaccine approved in India. The vaccine is approved for individuals aged 4–60 years and is administered as a two-dose schedule with a three-month interval.
Explanation
- Dengue is a mosquito-borne viral disease caused by the Dengue virus (DENV-1, DENV-2, DENV-3, DENV-4) and transmitted mainly by Aedes aegypti mosquitoes.
- QDENGA (TAK-003) is a live-attenuated tetravalent vaccine, designed to provide protection against all four dengue serotypes.
- Unlike earlier vaccines, pre-vaccination screening is not required, and it can be administered irrespective of prior dengue infection.
- Dengue can progress to severe dengue (dengue haemorrhagic fever/dengue shock syndrome) due to antibody-dependent enhancement (ADE) during secondary infection with a different serotype.
- Prevention relies on integrated vector management.
La Excellence IAS Academy, the best IAS coaching in Hyderabad, known for delivering quality content and conceptual clarity for UPSC 2026 preparation.
FOLLOW US ON:
◉ YouTube : https://www.youtube.com/@CivilsPrepTeam
◉ Facebook: https://www.facebook.com/LaExcellenceIAS
◉ Instagram: https://www.instagram.com/laexcellenceiasacademy/
GET IN TOUCH:
Contact us at info@laex.in, https://laex.in/contact-us/
or Call us @ +91 9052 29 2929, +91 9052 99 2929, +91 9154 24 2140
OUR BRANCHES:
Head Office: H No: 1-10-225A, Beside AEVA Fertility Center, Ashok Nagar Extension, VV Giri Nagar, Ashok Nagar, Hyderabad, 500020
Madhapur: Flat no: 301, survey no 58-60, Guttala begumpet Madhapur metro pillar: 1524, Rangareddy Hyderabad, Telangana 500081
Bangalore: Plot No: 99, 2nd floor, 80 Feet Road, Beside Poorvika Mobiles, Chandra Layout, Attiguppe, Near Vijaya Nagara, Bengaluru, 560040
QDENGA Vaccine: India’s First Approved Dengue Protection